Johnson & Johnson's (JNJ) Wins $1.67B Patent Verdict Versus Abbott Laboratories (ABT)
More News related to ABT
- Absolute Software Acquires LANrev product suite from Pole Position Software
- Abbott and the Abbott Fund Honored With Corporate Citizenship Award for International Community Service
- Abbott's Ibis Technology Named One of the Top Innovations for 2009 by The Scientist
- Goldman Sachs Removed Abbott Labs (ABT) From Buy List, Eli Lilly (LLY) From Sell List
- Abbot Labs (ABT) To Transfer TriCor Rights to Teva Pharma (TEVA) as Soon as 2011
More News related to JNJ
- Emerging Healthcare Launches Health Initiative
- ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities
- StockPreacher.com Issues Trading Outlook for Arena Pharmaceuticals Inc.
- Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
- Trading Outlook for BioElectronics Corporation Issued by StockPreacher.com
More News related to Corporate News
- After-Hours Movers 12/02: KTCC, PSS, SEAC, BAC Higher; SIGM, SNPS, ARO, JAS, VRTX Lower
- Trading Radar for 12/3: Marvell (MRVL), Toll Bros. (TOL), Del Monte (DLM), Smith & Wesson (SWHC) Report
- Unusual 11 Mid-Day Movers 12/02: ABCW, BIOF, GRH, STEM Higher; HEB, HDY, BGP, CBAK Lower
- Notable ETF Movers 12/2: GDX, TUR Up; UNG, USO, THD Down
- Notable Analyst Rating Changes 12/2: AMR/UAUA, RFMD, STI, SAY, KBH, BBT Upgraded; STZ, MTL, BWP, POM Downgraded
Centocor Ortho Biotech Inc., wholly-owned subsidiary of Johnson & Johnson (NYSE: JNJ), announced that a federal jury has returned a verdict of $1.67 billion against Abbott Laboratories (NYSE: ABT) in a patent infringement suit.
The patent in question relates to the company's anti-TNF class of arthritis treatments, and is co-owned by New York University and Centocor, for which Centocor is the exclusive licensee.
Related Categories
Corporate NewsHot List
Stocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
